Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want the quick path to Biodesix’s most revealing disclosures? Investors tracking blood-based diagnostic innovators like Biodesix (BDSX) often need to pinpoint reimbursement updates, R&D spend on new lung biomarkers, or insider stock moves before clinical data drops. This SEC filings hub answers those questions in one place.
Navigate straight to the document you need—whether it’s the BDSX quarterly earnings report 10-Q filing that details Nodify Lung revenue, the BDSX annual report 10-K simplified for risk factors around FDA laboratory-developed tests, or the BDSX proxy statement executive compensation that links pay to diagnostic pipeline milestones. Stock Titan’s AI reads every page, producing concise summaries so you can scan complex tables in seconds. That means BDSX SEC filings explained simply, without losing critical nuance.
Real-time alerts flag BDSX Form 4 insider transactions, letting you monitor executive stock activity the moment it hits EDGAR. Need context? Our platform connects each trade to material disclosures so you understand motive, not just movement. You’ll also find:
- BDSX 8-K material events explained for coverage-decision news or new assay launches
- BDSX earnings report filing analysis that compares quarter-over-quarter margin shifts
- BDSX executive stock transactions Form 4 with historical trend charts
From understanding BDSX SEC documents with AI to drilling into BDSX insider trading Form 4 transactions in real time, this page keeps equity analysts, healthcare investors, and strategic partners informed—without wading through hundreds of pages.
Biodesix (BDSX) reported a routine insider transaction for Chief Accounting Officer Chris Vazquez. On 11/10/2025, 31 shares of common stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes upon vesting, 13 shares were automatically sold at $7.62. Following these transactions, Vazquez directly owned 936 shares. Each RSU represents one share of common stock, and the RSUs vest in sixteen successive quarterly installments measured from February 8, 2022 and have no expiration date.
Biodesix (BDSX) insider transaction: Chief Development Officer Gary Pestano reported RSU vesting and a small tax sale on 11/10/2025. A total of 69 shares were issued upon RSU settlement (code M), and 23 shares of common stock were sold at $7.62 to cover taxes tied to the vesting.
Following these transactions, Pestano beneficially owned 7,939 shares directly. The filing notes all share figures reflect the one‑for‑twenty reverse stock split effective September 15, 2025, and that each RSU represents one share of common stock.
Biodesix (BDSX) Chief Commercial Officer Kieran O’Kane reported RSU vesting and a related sale on 11/10/2025. He acquired 75 shares of common stock upon RSU vesting (code M) and sold 25 shares at $7.62 to cover taxes upon vesting. Following these transactions, he directly owned 7,362 shares of common stock and held 73 RSUs.
The filing notes all figures reflect the 1-for-20 reverse stock split effective September 15, 2025. The RSUs vest in sixteen successive quarterly installments measured from February 8, 2022, subject to continued service. Prior ownership includes 309 shares purchased under the Employee Stock Purchase Plan on September 2, 2025.
Biodesix (BDSX) disclosed insider activity by its President & CEO and Director, Scott Hutton. On 11/10/2025, 611 shares of Common Stock were acquired upon RSU vesting, followed by an automatic sale of 189 shares at $7.62 to cover taxes. Following these transactions, the reporting person directly beneficially owned 37,311 shares.
The amounts reflect the one-for-twenty reverse stock split effective September 15, 2025. After the vesting event, 610 RSUs remained outstanding, with RSUs vesting in successive quarterly installments measured from February 8, 2022.
Biodesix (BDSX) reported an insider transaction by its CFO, Secretary & Treasurer, Robin Harper Cowie. On 11/10/2025, 158 shares of Common Stock were acquired upon the vesting of restricted stock units, adjusted for the one-for-twenty reverse stock split effective September 15, 2025. To cover taxes from the vesting, 50 shares were sold at $7.62. Following these transactions, the reporting person beneficially owned 13,147 shares directly.
Biodesix, Inc. (BDSX) filed its Q3 2025 10‑Q reporting higher revenue and continued losses. Revenue was $21.8 million for the quarter and $59.7 million year‑to‑date, while the quarterly net loss was $8.7 million and the nine‑month net loss was $31.3 million.
Cash and cash equivalents were $16.6 million and borrowings carried at $47.1 million. The company drew a $10.0 million Tranche C loan under its Perceptive Term Loan Facility and raised $5.0 million gross through its at‑the‑market program. Stockholders’ equity shifted to a deficit of $1.7 million.
Biodesix effected a 1‑for‑20 reverse stock split on September 15, 2025 and subsequently regained Nasdaq minimum bid price compliance. Shares outstanding were 7,955,685 as of October 28, 2025.
Biodesix, Inc. furnished an 8-K announcing its financial and operating results for the third quarter ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1 and incorporated by reference as stated. The company noted the information is furnished, not filed, under the Exchange Act.
John Patience, a director of Biodesix, Inc. (BDSX), reported receipt of 1,144 restricted stock units (RSUs) effective 09/30/2025. The filing notes a one-for-twenty reverse stock split effective 09/15/2025 and states the reported share figures have been adjusted for that split. The RSUs represent contingent rights to receive one share each and vest in three substantially equal installments on 06/30/2025, 09/30/2025, and 12/31/2025, generally subject to continued service, and have no expiration date. The report discloses indirect holdings through Patience Enterprises LP (107,664 shares), the John Patience Living Trust dated 7/23/1993 (241,480 shares), and holdings attributed to a spouse (2,649 shares). The Form is signed by Robin H. Cowie as attorney-in-fact for John Patience on 10/02/2025.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
